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Cell-based therapies have the potential to make a large contribution toward currently 
unmet patient need and thus effective manufacture of these products is essential. Many 
challenges must be overcome before this can become a reality and a better definition 
of the manufacturing requirements for cell-based products must be obtained. The aim 
of this study is to inform industry and academia of current cell-based therapy clinical 
development and to identify gaps in their manufacturing requirements. A total of 
1342 active cell-based therapy clinical trials have been identified and characterized 
based on cell type, target indication and trial phase. Multiple technologies have 
been assessed for the manufacture of these cell types in order to facilitate product 
translation and future process development.
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Regenerative medicine offers a transforma-
tive approach to healthcare, with the poten-
tial to not only treat, but cure disease. The 
therapeutic application of cells, or cell-based 
therapy, forms a fundamental part of this 
landscape and already has global revenues 
of over US$1 billion [1]. With an ever-
increasing number of cell-based therapies in 
the pipeline this industry, if properly devel-
oped, has the potential to provide significant 
health and wealth benefits throughout the 
world.
The use of live cell-based therapies in 
medicine is not a new concept. The first 
successful allogeneic human hematopoietic 
stem cell transplant took place in 1968 [2] 
and is now a routine clinical procedure for 
bone marrow regeneration. The true value 
of stem cell-based therapies was not explored 
until some two decades later when the thera-
peutically relevant cells were considered for 
the regeneration of skeletal tissue [3] and later 
for broader therapeutic utility [4]. This led to 
the commercial venture into cellular therapy 
by Osiris Therapeutics (NASDAQ:OSIR), 
who have since received market approval in 
Canada and New Zealand for ProchymalTM, 
a mesenchymal stem cell (MSC) therapy for 
juvenile graft versus host disease.
Since the turn of the millennium there 
has been a steady increase in the number 
of cell-based therapy clinical trials, with an 
increasing spread of phases and number of 
target indications [5]. This increased diver-
sity of target clinical indications has been 
largely driven by growing evidence of the 
trophic effects of infused cells, whereby the 
putative mechanism of action is by secre-
tion of proteins and paracrine factors rather 
than terminal engraftment [6]. Alongside 
adult stem cells, pluripotent stem cells have 
attracted significant interest for cell-based 
therapy applications due to their high pro-
liferative potential and ability to form any 
tissue in the body. Both embryonic stem cell 
and induced pluripotent stem cell-derived 
products are currently entering clinical 
development [7] but face many technical and 
ethical hurdles particularly around product 
safety [8].
Clinical activity in cell-based therapies 
is clearly converging upon a critical mass, 
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with over 300,000 patients treated with regulatory-
approved products since 1997 [9]. This does mean, 
however, that patient expectations are increasing and 
must be managed delicately to avoid a second wave of 
disillusionment in the sector, following the drop in 
commercial activity in the early 2000s [10]. In con-
junction with this, great emphasis must be placed on 
patient safety by avoiding the exploitation of patients 
engaged in ‘stem cell tourism’ and the off-label or unli-
censed use of stem cell-based therapies [11–13]. This is 
all part of a wider regulatory balance that on one hand 
ensures patient safety and on the other hand does not 
prevent much needed treatments reaching the clinic.
For the majority of clinical indications, the trans-
plantation of primary donor cells may not be sufficient 
to meet the clinical need and the expansion of cells in 
culture will be required to address the shortage of ther-
apeutically active cells available in the body. To ensure 
that these cell-based therapies can meet the needs of 
the patient, cells must be produced in sufficient num-
bers, with reproducible quality and at relatively low 
cost. For this to happen, suitable scalable manufactur-
ing processes must be developed either before or during 
the clinical assessment phase, with the final optimal 
process used to produce batches for Phase III clinical 
studies typically carried forward to commercial pro-
duction. The aim of these manufacturing processes is 
to significantly increase cell numbers without nega-
tively affecting the therapeutic potential of the cell, 
which is known to deteriorate with time in culture [14]. 
It is possible that the manufacturing lot size required to 
meet this need will be in the order of trillions of cells, 
though this is dependent on the dose requirements per 
patient and market size of each indication [15]. Current 
manual planar culture technology is not sufficient to 
meet this requirement and new manufacturing meth-
ods must be developed to drive down the cost of goods 
to produce cost effective therapies and achieve product 
reimbursement.
There are currently many challenges facing the cell-
based therapy industry particularly in the regulated 
manufacture of these products under GMP [16]. Con-
ventional bioprocesses use cells to produce therapeutic 
agents, which can then be isolated and purified with-
out the need to recover the cell. For the manufacture 
of cell-based therapies, retention of cell function and 
quality is of primary importance in order to preserve 
product efficacy [17]. This consideration is particularly 
pertinent, considering that a number of these cell types 
are adherent, meaning that they must be detached or 
harvested from a culture substrate, prior to down-
stream processing. To quantify this, effective manu-
facture is reliant on measuring these critical-to-quality 
attributes and establishing the allowable deviation of 
these product characteristics from a predetermined set 
point. The use of potency assays can provide a batch 
release test that validates whether the cell product is 
consistent, stable and of sufficient quality for thera-
peutic use, as well as providing a comparability met-
ric to validate process changes [18]. Stringent safety 
assays must also be considered for cell-based therapies 
as many current processes use animal-derived prod-
ucts during culture, which could lead to pathogen 
transfer or immune complications once infused into 
the recipient [19]. Additionally, the use of pluripotent 
stem cells brings a new set of safety challenges within 
downstream purification, ensuring that the unlimited 
growth potential of these cells is not transferred to the 
patient [20]. The requirement for high levels of process 
and product characterization will result in significant 
direct costs in all process stages, from establishment 
of a master cell bank (for allogeneic products), to final 
product testing.
Cell-based therapies are complex biological prod-
ucts that are sensitive to their environment and display 
intrinsic variability within a tightly regulated industry. 
Variation in the product can come from two sources: 
process input material and process conditions [21]. For 
allogeneic therapies, where cells from one patient can 
be given to many patients, this input variability can be 
reduced by careful selection of comparable input mate-
rial to the process. Alongside this, the variability in 
process conditions can be managed in part by automat-
ing the manufacturing process allowing for increased 
control and process capability [22–25]. This allogeneic 
or ‘off-the-shelf ’ business model for cell-based thera-
pies is far more akin to current biopharmaceuticals [26], 
where the product maintains long-term stability.
Conversely, autologous cell-based therapies, where 
cells are taken from a patient and returned to the same 
patient, represents a different manufacturing chal-
lenge as patient populations must be stratified to con-
trol this input variation. Issues surrounding the qual-
ity test burden and logistics of personalized (services 
based) medicine add to the complexity for large scale 
production and delivery of a cost effective autologous 
cell-based therapy [27]. Delivery of autologous cell-
based products can be complex due to the short term 
preservation methods used for transport and delivery, 
for example the shelf life of Provenge, an autologous 
peripheral blood mononuclear cell-based therapy sus-
pended in Lactated Ringer’s Injection solution is only 
18 h at 2–8°C [28]. Several allogeneic therapies in 
development are also shipped to clinical delivery sites 
in a noncryopreserved format. This results in the need 
to maintain a constant level of production, even when 
clinical demand may vary greatly, as noncryopreserved 
products typically have a shelf life on the order of 
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days and significant product wastage can occur. This 
increases overall product cost and requires larger 
batch sizes to be produced. Considering the range of 
potential cell-based therapies it is clear that multiple 
manufacturing models must be evaluated in order to 
fill the need of both universal (scale up) and person-
alized (scale out) therapies and control the associated 
biological variation to achieve a consistent product.
Given the diversity of cell types, disease indications 
and delivery pathways it is unlikely that there will be 
a ‘one-size-fits-all’ manufacturing platform for cell-
based therapies and therefore careful consideration 
must be given to process selection for commercial 
production during process definition, development 
and optimization, prior to clinical development. This 
study provides a snapshot of current cell-based therapy 
clinical trials by cell type, target clinical indication and 
trial phase and a comparative assessment of the process 
technology available to manufacture these cell-based 
therapies. The aim is twofold, firstly to inform indus-
try and academia of current clinical activity involving 
their cell type and secondly to identify the challenges 
associated with the manufacture of these cell-based 
therapies. This analysis will provide a comparison 
tool for manufacturing technology and facilitate the 
development clinical indication specific quality assays 
by providing an overview of the current target clinical 
indications for cell-based therapies.
Methodology
To initiate this study, we searched for the term ‘cell’ 
on the ClinicalTrials.gov database [29] to include all 
clinical trials involving the use of cells up to January 1, 
2014. This produced 29,467 results, which were fur-
ther sorted on the database to show only open trials 
reducing the number to 9700 which were extracted 
for analysis, providing an overview of the current 
cell-based therapy clinical trials landscape.
As this study is evaluating cell-based therapy clinical 
trials, the following British Standard Institute defini-
tion was used to classify these as a ‘therapy in which 
cells are administered to the body to the benefit of the 
recipient’ [30]. This excluded:
•	 Trials where the application of cell was not the 
main therapeutic goal of the study (i.e., studying 
the effect of a drug infused as part of a cell-based 
therapy);
•	 Trials that were observational (i.e., no direct 
application of cells to the patient);
•	 Duplicate trials (i.e., the same trial taking place in 
more than one country).
The 9700 trials were sorted manually one at a time 
by one individual to identify the true cell-based thera-
pies using the definition above and the listed exclusion 
criteria. This action left a database of 1342 cell-based 
therapy clinical trials that were checked to ensure the 
major industry clinical trials had been encompassed 
and further categorized as detailed below.
Cell type
Each of the 1342 clinical trials was assigned a cell type 
based on the clinical trial listing and the cell used for 
therapeutic benefit but where no cell type was indi-
cated, the cell type was listed as unknown. Where a 
clinical trial was assessing a combination of more than 
one cell type, both cell types were included in the 
study.
Cell group
The cell types in use for the clinical trials have been 
divided into multiple groups namely, hematopoietic 
cells (CD34+, mononuclear cells and whole marrow), 
MSCs, lymphocytes, dendritic cells, hepatocytes, 
endothelial cells, fibroblasts, myocytes, epithelial cells, 
islet cells, chondrocytes, renal cells, embryonic stem 
cells and other cells. The purpose of these groups is to 
show the spread of cell types in current active cell-based 
therapy clinical trials.
Clinical indication
Categorized based on clinical speciality and disease 
mechanism of action or where an indication falls into 
more than one category, by the greatest need. An exam-
ple of this is stroke, which is a vascular disease that 
manifests as a neurological disorder and therefore is 
categorized in neurology as this is where the cell-based 
therapy treatment would be targeted.
Trial phase
The clinical trial phase was taken from ClinicalTrials.
gov and divided into Phases I, II, III and IV. Where 
trials were in the transition between phases, only the 
completed phase was used (i.e., a listing of Phase I/II 
would be classified as Phase I).
This process yielded a thorough database of catego-
rized cell-based therapy clinical trials that are currently 
open as of January 1, 2014. Although this provides a 
comprehensive database of cell-based therapy clinical 
trials on ClinicalTrials.gov, it does have a limitation. 
ClinicalTrials.gov was initiated as a result of the US 
FDA Modernization Act of 1997 as a registry of clini-
cal trial information for federally and privately funded 
trials conducted under investigational new drug appli-
cations (later expanded under FDA Amendments Act 
of 2007). This means that clinical trials in the USA 
52 Regen. Med. (2015) 10(1) future science group
Review    Heathman, Nienow, McCall et al.
must be registered on ClinicalTrials.gov but clinical 
trials initiated in other countries are only included 
on a voluntary basis. Therefore, this method does not 
include all cell-based therapy clinical trials, just those 
registered through the National Institutes of Health. 
Limitations of this database have been previously dis-
cussed [31]. The methodology presented here will, how-
ever, contain the vast majority of cell-based therapy 
clinical trials and certainly a large enough sample to 
draw meaningful conclusions.
Results
Clinical trial landscape for cell-based therapy
Our search of the clinical trial database yielded a total 
of 1342 active clinical trials that were judged to be true 
cell-based therapies from the British Standard Institute 
definition as of January 1, 2014. The vast majority of 
these cell-based therapies are using hematopoietic cells 
(n = 444), MSCs (n = 382), lymphocytes (n = 253) 
and dendritic cells (n = 91) (Figure 1). The use of tissue 
specific cells is less prevalent, representing 114 of cur-
rent cell-based therapy activity with a mixture of cell 
types such as chondrocytes (n = 12), endothelial cells 
(n = 15), fibroblasts (n = 14), hepatocytes (n = 16), islet 
cells (n = 13) and neural cells (n = 13). Figure 2 shows 
the diversity of cell isolation sources represented from 
hematopoietic and MSC trials. The rapid increase in 
MSC activity is clear, with 382 clinical trials in progress 
from a number of isolation sources most notably 237 
of which are from the bone marrow, 61 from umbilical 
cord and 59 from adipose tissue. The use of pluripotent 
stem cell-derived products is rare, though there are six 
clinical trials involving embryonic stem cells. Interest-
ingly, all six involve differentiation into retinal pigment 
epithelium cells and are initiated by industry: CHA 
Bio & Diostech in Korea (two), Advanced Cell Tech-
nology (three) and Pfizer in the UK (in collaboration 
with University College London).
Disease indications targeted by cell-based 
therapy clinical trials
It is clear that the most common target for cell-based 
therapy clinical trials is oncology, which represents 
46% of all cell-based therapy clinical trials identi-
fied (Figure 1), due to the use of traditional blood cell 
and immune cell-based therapies for the treatment of 
various cancers. Aside from these traditional cell-based 
therapies, cardiology is the second largest clinical target 
with 88 clinical trials (Figure 1), 51 of which are using 
MSCs (Figure 3). Immunological disorders remain a 
key target for cell-based therapies (Figure 4) with disor-
ders such as graft versus host disease (n = 33), immune 
modulation following transplantation (n = 17) and 
Crohn’s disease (n = 16), as well as rheumatic disorders 
osteoarthritis (n = 15), lupus erythematosus (n = 9) 
and rheumatoid arthritis (n = 6) currently in Phase I 
Figure 1. Number of active clinical trials by cell type and target clinical indication. Displaying broader cell type 
categories of hematopoietic (blue), mesenchymal stem cells (red), immune cells (green), tissue-specific cells 
(orange), embryonic stem cells (purple) and other (aqua). 
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and above. Neurological indications also represent 
a significant target for novel cell-based therapies for 
indications such as multiple sclerosis, stroke and motor 
neuron disease (Figure 4). Figure 3 shows the broad 
therapeutic utility adopted for MSCs, with clinical 
indications covering all 18 clinical categories with the 
majority within cardiovascular, neurological and auto-
immune indications predominantly in Phase I. Like-
wise, tissue specific cells cover the majority of clini-
cal indication categories, owing to the diversity of cell 
populations within this category.
Cell-based therapy clinical trial phase
It is unsurprising that the majority of cell-based 
therapy clinical trials are in Phase I, with 232 MSC, 
146 lymphocyte and 118 hematopoietic cell clini-
cal trials (Figure 5). There is however, an increase in 
hematopoietic cell clinical trials moving to Phase II 
with 187 compared with 116 in Phase I. There are 
also four tissue specific cell-based clinical trials that 
have reached postmarket surveillance, or Phase IV 
(Figure 5). Most notable of these are the use of der-
mal fibroblasts for wound repair from Arita Medical 
(ReCellTM) and Organogenesis (ApligrafTM) as well as 
cell-based therapies to treat Type 2 diabetes and for 
cornea replacement. Figure 4 shows the major clini-
cal categories by specific disease targets, with the vast 
majority targeting hematological malignancies within 
oncology, with equal weighting in Phases I and II. 
Cardiovascular indications also have a similar number 
of clinical trials in Phases I and II, with ten clinical 
trials in Phase III and above. MSC clinical trials are 
also well represented in Phase II (n = 88) and are even 
seeing progression to Phase III (Figure 5). Neurology 
Figure 2. Current active cell therapy clinical trials showing the breakdown of the hematopoietic and mesenchymal 
stem cell groups the by cell isolation source.
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and rheumatology based indications that involve 
MSCs are mostly in Phase I (Figure 6), however clini-
cal development using bone marrow-derived MSCs 
to treat acute coronary syndrome, Crohn’s disease 
and graft versus host disease are seeing progress into 
Phase II and above, with clinical trials taking place all 
over the world.
Discussion
Clinical translation of mesenchymal stem 
cell-based therapies
It is clear that outside of the traditional cell-based 
therapies using blood and immune cells to treat 
cancer, the majority of novel clinical trial activity is 
involving MSCs. The commercial pathway for MSC 
therapies was initiated after they were branded in 
1991 by Arnold Caplan [3], leading to the genera-
tion of intellectual property by Osiris Therapeutics. 
The rebranding of MSCs has been used to generate 
intellectual property by defining a specific set of char-
acterization criteria for the cell, for example, Athersys 
Inc. are developing a product termed MultiStemTM, a 
Multipotent Adult Progenitor Cell therapy which has 
been patented under this name [32,33].
As the first clinical trials involving MSCs devel-
oped, the need for nomenclature and characterization 
standards led to the formation of the International 
Society for Cellular Therapy working group in 1992, 
who eventually published minimal criteria for MSCs 
in research [34,35]. The broad therapeutic utility cur-
rently adopted for MSC clinical indications was a 
product of work by Osiris Therapeutics [36] and led to a 
lot of publicity around the potential of stem cell-based 
therapies. The green shoots of industry that began to 
emerge in the 1990s soon dried up as the failure rate 
of clinical trials, the huge cash-burn and increased 
bankruptcy of cell-based therapy companies caused 
investors to lose confidence in the industry and as a 
Figure 4. Breakdown of the most prevalent clinical target groups from cell therapy clinical trials by disease and 
trial phase.
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result, the capital value of publicly traded companies 
plummeted from US$2.5 billion in 2000 to US$300 
million by the end of 2002 [10]. This decline was pre-
dominantly driven by a lack of fundamental under-
standing of the therapeutic mechanism of action of 
MSCs in vivo which is still under discussion [37]. This 
understanding will be imperative, as relevant potency 
assays must be used to optimize manufacturing pro-
cesses based on a single clinical indication, even if 
the same master cell line is to be used for multiple 
therapeutic targets.
Clinical work in the mid-2000s showed that the 
immunomodulatory properties of MSCs played a key 
role in their therapeutic potential [38,39], suppress-
ing tissue rejection by inhibiting the response of the 
patient’s lymphatic cells. This is reflected in Figure 6, 
as the use of MSCs for immunology and rheumatol-
ogy based indications are common and are progress-
ing through clinical development with five trials 
progressing to Phase III, one targeting osteo arthritis 
(Medipost), one targeting graft versus host disease 
(Mesoblast) and three targeting Crohn’s disease 
(Tigenix and two by Mesoblast). This demonstrates 
the increased emphasis that industry has placed on 
the immunomodulatory mechanism of action that 
MSCs have demonstrated. The mounting evidence 
that the therapeutic effect of MSCs is not mediated 
by engraftment and terminal differentiation but by 
cell secreted trophic factors is gaining increasing 
momentum with studies showing that donor DNA is 
only retained in the lungs, lymph nodes and intes-
tine following MSC infusion [40]. There is limited 
clinical evidence supporting the optimal method for 
therapeutic delivery of cell-based products [41] and it 
is likely that, as with manufacturing processes, deliv-
ery systems will be developed specifically for each 
therapeutic indication [42].
Case study: product manufacture during 
Phase I clinical trial
Since the discovery of embryonic stem cells in 1998 
[43], pluripotent stem cells have been considered a 
promising source of allogeneic stem cells for regenera-
tive therapies. In 2010 Geron Co. went into Phase I 
clinical trials with an allogeneic human embryonic 
stem cell (hESC)-derived oligodendrocyte progenitor 
product for the treatment of spinal cord injury. Despite 
no adverse safety issues with this hESC-derived ther-
apy, Geron Co. halted the clinical trial citing financial 
and regulatory issues [44]. Currently, all of the clinical 
trials involving hESCs are targeting ophthalmology 
related indications, in Stargardt’s macular dystrophy 
Figure 5. Breakdown of current active cell therapy clinical trials by cell group and trial phase.
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and dry age-related macular degeneration. Advanced 
Cell Technologies are sponsoring three of these clini-
cal trials in the UK and USA, treating these disorders 
with hESC-derived retinal pigment epithelium (RPE) 
cells. One of the key challenges in the manufacture 
of a pluripotent product is in the differentiation of 
the hESC into the therapeutically active cell, which 
can dramatically impact product yield. The Advanced 
Cell Technologies RPE product is manufactured from 
the GMP-grade MA09 hESC line, cultured on mito-
mycin-inactivated murine embryonic fibroblasts for 
three passages. Following the formation of embryoid 
bodies, pigmented RPE patches are isolated and puri-
fied [45], before further expansion and cryopreserva-
tion for clinical use. Product characterization takes 
place in-process and postcryopreservation, in the form 
of pathogen testing, karyotype analysis and purity [46]. 
Much of this manufacturing process is labor-intensive 
and requires operator intervention, which may not 
be amenable to automated and scalable manufac-
ture. Therefore, despite the positive safety data from 
these ESC clinical trials [44], it is clear that there are 
many manufacturing challenges that must be over-
come before these therapies can be translated through 
clinical trial and into commercial production.
Case study: manufacture for commercial 
production
It is clear from the clinical trial results in Figure 1, that 
the most prevalent clinical category for cell based ther-
apies is in oncology, with immune cells contributing to 
around half of these cell-based therapies. Sipuleucel-T is 
an autologous active cell-based immunotherapy prod-
uct designed to stimulate an immune response against 
prostate cancer from Dendreon Corporation (WA, 
USA) [47]. In 2010, Sipuleucel-T (Provenge®) became 
the first FDA-approved autologous cell-based therapy, 
providing a scale-out service based approach to product 
manufacture and delivery. Patient cells are collected via 
leukapheresis [48] and cold shipped to a manufactur-
ing site, where the cells are manipulated under GMP 
conditions to isolate and activate the target immune 
cells. The activated cell-based immune therapy is then 
cold shipped back to the patient to be reinfused, which 
is repeated three times to deliver the full therapeutic 
dose. Dendreon Corporation operates patient logistics 
from a central location, with distributed manufactur-
ing taking place at multiple sites across the USA. This 
product handling and manipulation is largely manual 
and has led to high product operating costs, increasing 
the product cost of goods and therefore creating a high 
Figure 6. Current active cell therapy clinical trials involving mesenchymal stem cells showing target clinical 
indications by target disease and trial phase.
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reimbursement price, which is US$93,000 per patient. 
Efforts have been made to reduce the cost of goods by 
implementing automated process steps, with the inten-
tion of reducing these high operating costs. This case 
study highlights the importance of considering func-
tionally closed and automated scale out processes early 
in clinical development as this will reduce the overall 
cost of goods during commercial production [49].
A proposed clinical development pathway would be 
to produce Phase I material in a manual, semiclosed 
process which could then be transferred to a scalable, 
closed and automated manufacturing process follow-
ing the success of the initial clinical trials. This model 
would allow for reduced capital investment to evalu-
ate the product at Phase I but then would transfer the 
process in a timely manner, ensuring a scalable and 
cost effective product supply for late stage clinical 
development and commercial supply. Considering the 
high cost and increased risk of validating sterilization 
cycles, it is likely that these closed-processes will utilize 
disposable technology, mimicking current therapeutic 
protein process development [50].
Progress from clinical development to product 
manufacture
Industry progression towards the successful manufac-
ture of cell-based therapies is evident by international 
cooperation on the formation of global reference ‘ruler’ 
standards and protocols to facilitate manufacturing 
comparability of MSCs [51]. This will facilitate the 
development of consistent manufacturing processes 
across multiple sites and allow for a method to define 
each cell line. Defining desirable product characteris-
tics is critical and will form the basis of release tests as 
well as setting the tolerances on the process, allowing 
for systematic product development and optimization.
A further sign that the commercial market for MSC 
application is increasing in competitiveness is the drive 
by companies such as Athersys and Osiris to clearly 
differentiate their product and its production process 
from ‘generic’ hMSCs. This phenomenon parallels 
the clinical development of MACITM (by Genzyme) 
and CCITM (by TiGenix) where companies actively 
sought to distance their products from legacy clinical 
data on the use of Autologous Chondrocyte Implanta-
tion, which was inconclusive in demonstrating cost–
effectiveness [14]. This approach to cell-based product 
development is largely driven by a fundamental lack of 
understanding of the product mechanism of action, as 
companies must differentiate their product to avoid a 
race to the bottom, whereby a lower cost therapy has 
an increased chance of reimbursement. Without the 
knowledge of the how these cell-based therapies elicit 
therapeutic benefit, manufacturing processes cannot 
be optimized to maximize this function and will inevi-
tably be surpassed by lower cost therapies. Given the 
importance of regulation on the production of cell-
based therapies, it is perhaps unsurprising that in the 
race to successfully commercialize cell products, com-
panies have begun to raise the regulatory bar as a tactic 
to disrupt competitor companies. This action has the 
potential to hinder smaller companies who do not have 
the financial resource to comply with this increasing 
regulatory burden.
A further hallmark of the commercial progress of 
MSC therapies is the move towards developing auto-
mated processes as well as the implementation of func-
tionally closed manufacturing systems and consider-
ation of the associated logistics, supply chain and cost 
of goods [52]. Significant UK government investment 
in the form of the Cell Therapy Catapult has been 
tasked with ‘derisking’ cell-based therapy develop-
ment for industry by providing a ‘center of excellence’ 
to bridge the current translation gap in the industry 
[53]. Outside of the UK, additional institutes have been 
established to provide resources in Canada (Centre for 
Commercialization of Regenerative Medicine) and the 
USA (California Institute for Regenerative Medicine 
and the National Institutes of Health) to facilitate 
this translational process. Despite this progress, there 
remains a requirement for a better understanding of 
potential manufacturing platforms and how they can 
be best utilized for cell-based therapy production.
Expansion technologies to achieve clinical scale 
manufacture
With cell-based therapies moving towards commercial-
ization and multiple clinical trials in late stage develop-
ment, it is clear that selecting suitable manufacturing 
technology is becoming increasingly important. It is 
imperative that potential pitfalls in developing scalable 
manufacturing methods are identified at an early stage 
and strategies are implemented that can streamline this 
development pathway (Table 1). A key consideration 
for streamlining this pathway is the tradeoff between 
clean room space and ongoing commercial supply as 
patient numbers increase from clinical development to 
commercial production. For an autologous therapy if 
you were treating, for example, 100 patients in a typical 
2-week process for a Phase III clinical trial, you would 
likely require four clean room facilities in order to sep-
arate each patient lot. This is assuming that the pro-
cess is not entirely closed and therefore each lot must 
be segregated to avoid cross contamination. The issues 
then arise if the product is successful and commer-
cial production is carried out using the same process 
for say 1000 or even 10,000 patients per year, where 
the clean room and personnel requirements increase 
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10-fold or 100-fold respectively, making the product 
cost-prohibitive at this scale. This will drive the devel-
opment of expansion platforms that are fully closed, 
so that multiple patient lots can be manufactured in 
the same facility, greatly reducing fixed and operating 
costs as the product moves toward commercial produc-
tion. Table 2 shows the number doses per lot achievable 
for multiple expansion technologies currently available 
based on an allogeneic MSC treatment for myocardial 
infarction [54] requiring 35–350 million cells per dose. 
This demonstrates the challenge of manufacturing an 
MSC based product for 10,000 patients per year, given 
the number of doses per lot achievable using current 
expansion technology. 
A manufacturing process that reduces biological 
divergence will inevitably yield a more consistent and 
higher quality product. This biological divergence is 
typical of cell expansion processes, whereby small 
changes to the cell environment at the start of culture 
will lead to large changes by the time the product is 
Table 1. Strategies for streamlining the path to scaled clinical manufacturing.
Process requirement Description Benefits from implementation
Implement end to end 
closed processing
Utilize upstream and downstream processes 
that can be interconnected in a functionally 
closed manner
While manufacturing systems are becoming 
functionally closed, the reliance on open 
or non-closed inter process steps and 
manipulations necessitates the use of a clean 
room facility – massively increasing fixed costs of 
manufacture
Use processing steps and 
processes with the highest 
practicable expansion ratio†
Maximize product output for a given 
master cell bank population or donor cell 
population
Any reduction in the number of unit processes 
that must be validated to pass through process 
qualification significantly reduces the cost of 
pre- and post-market validation
Increase process capability Increase stability and consistency of 
individual process outputs
Reduce process output variation will provide a 
more consistent utilization of a manufacturers 
fixed cost base. This in turn improves operational 
costs and reduces overall COGS
Increase inter-process 
pooling tolerances
All manufacturing platforms have a limit 
in the amount of surface area that can 
be manipulated (seeded or harvested) 
per unit time. This limit, in combination 
with cell pooling time tolerances between 
processing stages limits the effective batch 
size that may be cultured
Increase in overall batch size that may be 
achieved. For scale out systems such as closed 
single use bioreactors or the manual/automated 
manipulation of planar vessels an increase in 
pooling time tolerance could yield cost reductions 
in the form of reduced manufacturing labor, 
increased capacity utilization
Keep COGS low in short 
term while maintaining 
cost headroom
Develop a process that has a (realistic) 
reimbursable price point at all stages 
of scale, as market adoption rates are 
typically slow
Cell therapy manufacturing companies with 
approved products have struggled to achieve 
routine reimbursement at a level that would 
enable investment in facilities and process 
improvements that would reduce their costs. This 
effectively traps companies in a difficult financial 
position. Companies that maintain low COGS 
during clinical development can reinvest in process 
improvement and scale as they enter the market
Implement intermediate 
cryopreservation stages
Autologous – implement a cryopreservation 
step between manufacturing and product 
delivery 
Allogeneic – implement multiple in-process 
banking stages between cell sourcing, 
expansion and product delivery
In allogeneic manufacturing intermediate 
cryopreservation stages allow a more efficient use 
of master bank cell populations at low production 
capacities. Its also allows different stages of the 
process to be scaled up independently, allowing 
a staged validation program. In both autologous 
and allogeneic manufacturing strategies this 
reduces the need to release products at risk 
before end stage quality and safety testing is 
complete
†Expansion ratio defined as the output of cells divided by the input population. 
COGS: Cost of goods.
www.futuremedicine.com 59future science group
The translation of cell-based therapies    Review
harvested. This has been demonstrated in the cul-
ture of embryonic stem cells whereby changes to dis-
solved oxygen levels in the culture medium can lead to 
changes in cell growth characteristics [55] and differ-
entiation potential [56]. This potential divergence can 
be limited by reducing the heterogeneity of the culture 
conditions via mixing, so that the cell microenviron-
ment remains consistent throughout the culture. Tech-
nology that does not induce mixing such as T-flasks 
will potentially suffer from heterogeneity in physical, 
chemical and hence physiological conditions, although 
it can also exist in other forms. Packed/fluidized-bed 
bioreactors, due to their high density will invariably 
suffer from axial concentration gradients as medium 
flows though the bed, particularly as the scale increases. 
Hollow fiber reactors have the potential to introduce 
heterogeneity via longitudinal concentration gradi-
ents as medium or dissociation reagent flowing down 
the bioreactor changes with distance through the 
fiber (under plug flow). Although these factors could 
impact the consistency of the product, there is a lack 
of evidence to back this up and far more work will be 
required to fully understand and develop the various 
manufacturing processes for cell-based therapies.
A lack of online process control is a key barrier for 
the consistent manufacture of cell-based therapies. 
Expansion technologies such as rotating flasks and 
multilayer flasks lack the capability for online cell 
visualization which could form the basis for a non-
invasive control strategy based on cell coverage of a 
surface [57]. These technologies as well as T-flask auto-
mation currently lack the ability for online medium 
sampling which prohibits the control of key nutrient 
and metabolite concentrations, a staple of process 
control in the bioprocessing industry. Without an 
effective process control metric, expansion technology 
will suffer when attempting to maintain product con-
sistency and will incur a higher cost for product valida-
tion. Process control strategies are poorly understood 
for novel cell expansion technologies, however are rou-
tine in stirred tank bioreactors for current bioprocesses 
[58,59]. In addition to this, the physical characteriza-
tion of the stirred reactor system is well understood 
and can also be directly translated from traditional 
bioprocesses [60–62]. This development is analogous to 
process analytical technology (PAT) [63] in the current 
biopharmaceutical industry [64] and could be used as a 
model for the cell-based therapy process development.
The efficient harvest of cell-based therapies repre-
sents one of the few deviations from traditional biopro-
cessing and must be designed based on cell sensitivity 
and the pooling time limitations of the product. Scale-
out processes such as rotating flasks [65,66], T-flasks [22] 
and multilayer flasks [67] will require high cell pooling 
times which will limit the effective scale to which these 
therapies can be manufactured as product quality will 
likely reduce during the pooling process (Table 2). For 
cell-based therapies that are surface-adherent, the dis-
sociation of the cell from the surface is required dur-
ing the expansion process. This unique constraint of 
cell-based therapy manufacture is often overlooked 
but has been considered for packed/fluidized bed 
[68], hollow fiber [69] and stirred tank bioreactors [70]. 
Rocking-motion [71,72] and pneumatically driven bio-
reactors [62,73] have been previously employed for sus-
pension cell culture. However, transferring these sys-
tems to surface-adherent cell types will likely require 
an additional process step to transfer the culture to a 
Table 2. Potential scale per lot and harvest constraints for various cell therapy manufacturing platforms.
Expansion technology Estimated scale per lot Estimated doses per lot Adherent cell harvest
Surface 
area, cm2
Harvest 
volume, l
Number of 
cells (billion)
35 million 
cells per 
dose
350 million 
cells per 
dose
Detachment 
efficiency
Pooling 
time
Adherent Rotating flasks 850,000 100 21.30  609 61  Low High
Packed/fluidized 440,000 5 11.00  314 31  Medium Medium
Hollow fiber 210,000 5 0.50  14 1  Medium Medium 
T-flask 
(automated)
225,000 50 0.56  16 2  High High
Multilayer flask 400,000 30 10.00  286 29  High High
Adherent 
and 
suspension
Stirred tank >4,000,000 >1000 >100.00  >2857 >286  High Low
Rocking-motion 2,000,000 500 50.00  1429 143  Low Low
Pneumatically 
driven
2,000,000 500 50.00  1429 143  Low Low
In situ detachment efficiency: low <50%, medium 50–90% and high >90%.
Pooling time: low <1 h, medium 1–5 h, high >5 h.
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harvest vessel, allowing for increased agitation to pro-
mote efficient detachment and harvest of cells from 
microcarriers, which may not be sufficient in these sys-
tems [74]. A further challenge will emerge if the cells 
are required to be dissociated during the process (i.e., if 
bead-to-bead transfer does not occur at a high enough 
rate to support one step expansion). This will add addi-
tional steps to the process and will likely influence the 
design and optimization of other aspects of the process, 
such as agitation strategy and culture medium.
Although much work is yet to be done on calcu-
lating the optimum volume for expanding cell-based 
products in stirred tank reactors, current estimates 
put the maximum value at around 1000 l [75]. It 
should be noted however, that industrial scale mam-
malian cell culture, once considered to be limited to a 
similar scale is now routinely operated at greater than 
10,000 l [62,76]. Similar gains in effective cells per 
batch can also be made by increasing the microcarrier 
concentration, which is currently far from optimal for 
suspension based systems [77].
One feature that is a fundamental aspect of all cul-
ture processes is the need to supply oxygen to the cells. 
Due to its limited solubility, this supply is required to 
be provided continuously. As the cell density increases, 
it becomes necessary to provide that oxygen by sparg-
ing; typically with air, which also strips out the car-
bon dioxide produced [78]. For free suspension animal 
cells, sparging has required the inclusion in the media 
of protective agents, almost always the surfactant, Plu-
ronicTM F68, as bursting bubbles are detrimental to cell 
viability [62]. Because the cell densities reached to date 
and the specific oxygen uptake rate of MSCs [77] and 
embryonic stem cells [79], for example, are both low, 
such issues have not yet been addressed but will need to 
be as the density increases, especially since the presence 
of these protective agents in final product formulations 
may be an issue. For pneumatically driven bioreactors 
[62,73], bubbling gas is inherent to the way they function 
and therefore potential cell damage must be considered 
during the appraisal of expansion technology.
It is clear that other than stirred bioreactors, there 
is a distinct lack of comparable and peer reviewed data 
for the majority of manufacturing platforms discussed 
in this study. This could potentially be to the detriment 
of the field, as without reliable information to inform 
technology appraisal, process development is likely to 
default to stirred tank bioreactors due to the strong leg-
acy data that exists for large scale mammalian cell cul-
ture. On the other hand, there is nothing to be gained 
by innovating unnecessarily. Many of the potential 
manufacturing platforms mentioned here were consid-
ered in the 1980s for culturing animal cells, when it 
was considered that because they lacked a cell wall, it 
would be impossible to do so in the presence of rotat-
ing stirrers. Yet today, whether in single use systems, at 
bench scale or the largest commercial scale, stirred bio-
reactors are commonplace in the biotechnology indus-
try [80]. Indeed, they are now being preferred industri-
ally even for clone selection in robotically controlled 
microbioreactors (ambrTM) at the 15 ml scale [81].
Conclusion
Providing an overview of the current cell-based ther-
apy landscape has shown the breadth and diversity of 
the current cell-based therapies in clinical develop-
ment. With an increasing number of cell types and 
clinical indications being assessed, it is clear that con-
sideration must be given to how these products will be 
manufactured and subsequently delivered to patients 
on a clinically relevant scale. Although, several manu-
facturing systems are already available for the expan-
sion and manipulation of therapeutically relevant 
cells, an optimal and universal manufacturing plat-
form does not yet exist and may not be attainable due 
to the variety of cell types and clinical applications. 
With the exception of MSCs, most therapeutically 
relevant cell types have only been demonstrated on 
a subset of the broad range of available platforms. 
Developers considering the range of available manu-
facturing technologies need to balance the competing 
pressures discussed. Nevertheless, the fact that both 
MSC culture and harvest have now been effectively 
demonstrated in stirred bioreactors based on sound 
physical principles is encouraging, especially given the 
inherent flexibility and controllability of this technol-
ogy; and its success with free suspension and adherent 
animal cells from the 15 ml to the 25,000 l scale.
As an industry, cell-based therapies are still in the 
early stages of clinical development. It is clear that we 
must better understand the quality of our cell-based 
products in order to form a stable base for process eval-
uation and development. Investment in cell-based ther-
apy manufacturing in the UK has created an urgent 
need to better understand these cell-based therapy 
products to facilitate successful manufacture based on 
strong clinical data demonstrating product efficacy. It 
is likely that there will be bespoke manufacturing pro-
cesses for each of these cell-based products as well as 
‘generic’ cell-based therapy products driven by this fun-
damental lack of product understanding, with a move 
toward functionally closed and single-use technology.
Future perspective
Moving forward, we must better characterize cell-
based therapy clinical trials with accessible informa-
tion for a host of variables, including cell dose, patient 
numbers and cell providence. This will allow for effi-
www.futuremedicine.com 61future science group
The translation of cell-based therapies    Review
cient and accurate data collection on cell-based ther-
apy clinical trials, facilitating decision making across 
the cell-based therapy sector. As understanding of the 
cell-based products increases, we will likely experience 
step change improvements in manufacturing capabil-
ity. However, despite the current progress, we must 
recognize that cell-based therapy is still a relatively 
green industry with great potential yet to be realized.
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Executive summary
Aims
•	 Inform industry and academia of current clinical activity involving the cell type with which they work.
•	 Identify gaps in the manufacturing requirements for cell-based therapies.
Materials & methods
•	 Searched for the term ‘cell’ on ClinicalTrials.gov to include all clinical trials involving the use of cells up to 1 
January 2014.
•	 Results were further sorted on the database to show only open trials that conformed to the definition of a 
cell-based therapy.
Clinical translation of mesenchymal stem cell-based therapies
•	 Lack of fundamental understanding of the therapeutic mechanism of action of MSCs in vivo must be 
overcome to facilitate process development and optimization.
•	 There is limited clinical evidence supporting the optimal method for delivery of cell-based products and it is 
likely that they will be developed specifically for each therapeutic indication.
Progress from clinical development to product manufacture
•	 Progress reflected by development of automated processes, reference standards and implementation of 
functionally closed manufacturing systems.
•	 Companies must differentiate their product to avoid a race to the bottom, whereby a lower cost therapy has 
an increased chance of reimbursement.
Expansion technologies to achieve clinical scale manufacture
•	 Imperative that potential pitfalls in developing scalable manufacturing methods are identified at an early 
stage and strategies are implemented that can streamline this development pathway.
•	 Consideration must be given to cell harvest and pooling time limits as they represent key deviations from 
traditional bioprocesses.
•	 Other than stirred reactors with cells attached to microcarriers, there is a lack of comparable data for the 
majority of the cell-based manufacturing technologies.
Conclusion
•	 Multiple manufacturing platforms will likely be required to cover the diversity of cell types, clinical indications 
and business models.
•	 A greater understanding of cell quality metrics are required for bioprocess development.
Future perspective
•	 Need to better characterize cell-based therapy clinical trials and data should be immediately accessible.
•	 As understanding of the cell-based products increases, we will likely experience step change improvements in 
manufacturing capability.
•	 Despite the current progress, we must recognize that cell-based therapy is still a relatively green industry with 
great potential yet to be realized.
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